학술논문
Amivantamab plus chemotherapy with and without lazertinib in EGFR-mutant advanced NSCLC after disease progression on osimertinib: primary results from the phase III MARIPOSA-2 study
Document Type
Article
Author
Passaro, A.; Wang, J.; Wang, Y.; Lee, S.-H.; Melosky, B.; Shih, J.-Y.; Azuma, K.; Juan-Vidal, O.; Cobo, M.; Felip, E.; Girard, N.; Cortot, A.B.; Califano, R.; Cappuzzo, F.; Owen, S.; Popat, S.; Tan, J.-L.; Salinas, J.; Tomasini, P.; Gentzler, R.D.; William, W.N., Jr.; Reckamp, K.L.; Takahashi, T.; Ganguly, S.; Kowalski, D.M.; Bearz, A.; MacKean, M.; Barala, P.; Bourla, A.B.; Girvin, A.; Greger, J.; Millington, D.; Withelder, M.; Xie, J.; Sun, T.; Shah, S.; Diorio, B.; Knoblauch, R.E.; Bauml, J.M.; Campelo, R.G.; Cho, B.C.
Source
In Annals of Oncology January 2024 35(1):77-90
Subject
Language
ISSN
0923-7534